Short	O
pigment	O
epithelial	O
-	O
derived	O
factor	O
-	O
derived	O
peptide	O
inhibits	O
angiogenesis	O
and	O
tumor	B-Cancer
growth	O
.	O

PURPOSE	O
:	O
Pigment	O
epithelial	O
-	O
derived	O
factor	O
(	O
PEDF	O
)	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
with	O
multiple	O
other	O
functions	O
,	O
some	O
of	O
which	O
enhance	O
tumor	B-Cancer
growth	O
.	O

Our	O
previous	O
studies	O
mapped	O
PEDF	O
antiangiogenic	O
and	O
prosurvival	O
activities	O
to	O
distinct	O
epitopes	O
.	O

This	O
study	O
was	O
aimed	O
to	O
determine	O
the	O
minimal	O
fragment	O
of	O
PEDF	O
,	O
which	O
maintains	O
antiangiogenic	O
and	O
antitumor	B-Cancer
efficacy	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
analyzed	O
antigenicity	O
,	O
hydrophilicity	O
,	O
and	O
charge	O
distribution	O
of	O
the	O
angioinhibitory	O
epitope	O
(	O
the	O
34	O
-	O
mer	O
)	O
and	O
designed	O
three	O
peptides	O
covering	O
its	O
COOH	O
terminus	O
,	O
P14	O
,	O
P18	O
,	O
and	O
P23	O
.	O

We	O
analyzed	O
their	O
ability	O
to	O
block	O
endothelial	B-Cell
cell	I-Cell
chemotaxis	O
and	O
induce	O
apoptosis	O
in	O
vitro	O
and	O
their	O
antiangiogenic	O
activity	O
in	O
vivo	O
.	O

The	O
selected	O
peptide	O
was	O
tested	O
for	O
the	O
antitumor	B-Cancer
activity	O
against	O
mildly	O
aggressive	O
xenografted	O
prostate	B-Cancer
carcinoma	I-Cancer
and	O
highly	O
aggressive	O
renal	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
.	O

To	O
verify	O
that	O
P18	O
acts	O
in	O
the	O
same	O
manner	O
as	O
PEDF	O
,	O
we	O
used	O
immunohistochemistry	O
to	O
measure	O
PEDF	O
targets	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
,	O
and	O
CD95	O
ligand	O
expression	O
in	O
P18	O
-	O
treated	O
vasculature	B-Multi-tissue_structure
.	O

RESULTS	O
:	O
P14	O
and	O
P18	O
blocked	O
endothelial	B-Cell
cell	I-Cell
chemotaxis	O
;	O
P18	O
and	O
P23	O
induced	O
apoptosis	O
.	O

P18	O
showed	O
the	O
highest	O
IC50	O
and	O
blocked	O
angiogenesis	O
in	O
vivo	O
:	O
P23	O
was	O
inactive	O
and	O
P14	O
was	O
proangiogenic	O
.	O

P18	O
increased	O
the	O
production	O
of	O
CD95	O
ligand	O
and	O
reduced	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
by	O
the	O
endothelial	B-Cell
cells	I-Cell
in	O
vivo	O
.	O

In	O
tumor	B-Cancer
studies	O
,	O
P18	O
was	O
more	O
effective	O
in	O
blocking	O
the	O
angiogenesis	O
and	O
growth	O
of	O
the	O
prostate	B-Cancer
cancer	I-Cancer
than	O
parental	O
34	O
-	O
mer	O
;	O
in	O
the	O
renal	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
,	O
P18	O
strongly	O
decreased	O
angiogenesis	O
and	O
halted	O
the	O
progression	O
of	O
established	O
tumors	B-Cancer
.	O

CONCLUSIONS	O
:	O
P18	O
is	O
a	O
novel	O
and	O
potent	O
antiangiogenic	O
biotherapeutic	O
agent	O
that	O
has	O
potential	O
to	O
be	O
developed	O
for	O
the	O
treatment	O
of	O
prostate	B-Cancer
and	O
renal	B-Cancer
cancer	I-Cancer
.	O

